Pourzia, Alexandra L.
Olson, Michael L. http://orcid.org/0000-0002-1566-2029
Bailey, Stefanie R. http://orcid.org/0000-0002-1175-521X
Boroughs, Angela C.
Aryal, Aditi
Ryan, Jeremy http://orcid.org/0000-0002-3327-1283
Maus, Marcela V. http://orcid.org/0000-0002-7578-0393
Letai, Anthony http://orcid.org/0000-0002-1993-9013
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of General Medical Sciences (T32 GM007753)
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R35 CA242427)
Article History
Received: 22 November 2021
Revised: 21 February 2023
Accepted: 9 March 2023
First Online: 13 April 2023
Competing interests
: AGL declares membership on scientific advisory boards for Zentalis Pharmaceuticals, Anji Oncology, and Flash Therapeutics, and his laboratory has received research support from Novartis; and is an inventor on patents related to BH3 profiling held by Dana-Farber Cancer Institute. MVM is an inventor on patents related to adoptive cell therapies, held by Massachusetts General Hospital and University of Pennsylvania (some licensed to Novartis). MVM holds equity in TCR2 and Century Therapeutics, and has served as a consultant for multiple companies involved in cell therapies; consultant for: Adaptimmune, Agenus, Allogene, Arcellx, Astellas, AstraZeneca, Atara, Bayer, BMS, Cabaletta Bio (SAB), Cellectis (SAB), CRISPR therapeutics, In8bio (SAB), Innovakine, Intellia, GSK, Kite Pharma, Micromedicine, Novartis, TCR2 (SAB), Tmunity, Torque, and WindMIL (SAB); Grant/Research support: CRISPR therapeutics, Kite Pharma, Servier, Novartis; Stockholder: Century Therapeutics, TCR2, Ichnos; Board of Directors: Ichnos Sciences. All other authors declare no conflict of interest.